Alivus Life Sciences Q2 Net Profit Soars 51% YoY

Alivus Life Sciences Limited recorded a net profit of Rs 1,967.45 million for the quarter ended September 30, 2026, marking a 51.3% increase over the same period last year. Revenue from operations grew to Rs 6,819.87 million, up 16.0% from Rs 5,879.80 million in Q2 FY26.

Reader Takeaway: Robust operational leverage drove profit growth, with investors now watching the new Brazil subsidiary's integration and performance.

What just happened

Alivus Life Sciences announced its Q2 FY27 standalone results on the BSE. The company demonstrated significant margin expansion, with profit before tax growing by 50.4% to Rs 2,619.74 million. Earnings per share (EPS) rose to Rs 16.02, compared to Rs 10.60 in the prior year's corresponding quarter.

Why this matters

The data reflects strong operational efficiency, as profit growth substantially outpaced the 16% revenue increase. This suggests that the company is effectively managing its core API (Active Pharmaceutical Ingredient) business costs.

What changes now

The company has incorporated a wholly-owned subsidiary, Alivus Life Sciences Do Brasil Ltda., in Sao Paulo. While it has yet to commence operations or impact the consolidated financials, this move marks the company’s intent to expand its international presence. Additionally, the equity capital base saw a marginal increase to Rs 245.54 million due to the allotment of 32,000 shares under the ESOP 2021 scheme.

Context metrics

The company reported its results on a standalone basis as the new Brazilian subsidiary had no financial transactions to consolidate by the quarter's end. The statutory auditor has provided an unmodified review conclusion, indicating no significant discrepancies in the reported figures.

What to track next

Investors should monitor the scaling of the Brazil operations in the coming quarters and whether the company can maintain these elevated profit margins amidst changing API market dynamics.